Clinical Trial Update: Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing apixaban to dual antiplatelet therapy after left atrial appendage occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Left Atrial Appendage Occlusion

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: DR. XAVIER FREIXA | Conditions: Left Atrial Appendage Occlusion | Phase 4 | Status: COMPLETED